CG
BCRX icon

Cutler Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Cutler Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,443
Closed -$18.6K – 4909
2022
Q2 		$15K Sell
1,443
-7,047
-83% -$72.7K ﹤0.01% 2885
2022
Q1 		$138K Buy
8,490
+2,274
+37% +$36.5K 0.01% 1455
2021
Q4 		$86K Sell
6,216
-16,844
-73% -$223K ﹤0.01% 1967
2021
Q3 		$331K Buy
23,060
+15,160
+192% +$239K 0.01% 1023
2021
Q2 		$124K Buy
+7,900
New +$107K 0.01% 1692
2019
Q3 		– Sell
-2,400
Closed -$9K – 4061
2019
Q2 		$9K Sell
2,400
-1,900
-44% -$11.4K ﹤0.01% 2724
2019
Q1 		$35K Buy
4,300
+4,100
+2,050% +$35.1K ﹤0.01% 1648
2018
Q4 		$1K Hold
200
– – ﹤0.01% 3558
2018
Q3 		$1K Sell
200
-500
-71% -$3.36K ﹤0.01% 3692
2018
Q2 		$4K Buy
700
+500
+250% +$2.75K ﹤0.01% 3202
2018
Q1 		$0 Buy
200
+100
+100% +$514 ﹤0.01% 4445
2017
Q4 		$0 Sell
100
-8,332
-99% -$40.4K ﹤0.01% 4898
2017
Q3 		$44K Sell
8,432
-3,560
-30% -$18.2K ﹤0.01% 2356
2017
Q2 		$66K Buy
11,992
+1,420
+13% +$8.65K ﹤0.01% 2201
2017
Q1 		$88K Sell
10,572
-6,328
-37% -$44K ﹤0.01% 1855
2016
Q4 		$106K Buy
16,900
+1,500
+10% +$7.8K ﹤0.01% 1857
2016
Q3 		$67K Sell
15,400
-22,026
-59% -$88K ﹤0.01% 2166
2016
Q2 		$106K Sell
37,426
-600
-2% -$1.86K 0.01% 1634
2016
Q1 		$107K Buy
38,026
+18,400
+94% +$81.6K 0.01% 1543
2015
Q4 		$202K Buy
+19,626
New +$195K 0.01% 1182

Other funds holding BCRX

AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Cutler Group's BCRX Position: Q3 2022 in Review

Cutler Group sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2022, closing a stake of 1,443 shares — an estimated $18.6K sold.

Cutler Group first reported a position in BCRX in Q4 2015 and held it in 20 quarters. The position peaked at $331K in Q3 2021. 234 funds tracked by Wall St. Rank hold BCRX as of Q3 2022.

  • Cutler Group reported no remaining BioCryst Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Cutler Group sold 1,443 BioCryst Pharmaceuticals shares in Q3 2022, an estimated $18.6K.
  • Cutler Group first reported a position in BioCryst Pharmaceuticals in Q4 2015 and held it in 20 quarters.
  • Cutler Group's BioCryst Pharmaceuticals position peaked at $331K in Q3 2021.
  • 234 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2022.

Based on Cutler Group's 13F filing for Q3 2022, filed 25 Oct 2022.